Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says

This article was originally published in The Pink Sheet Daily

Executive Summary

University of Kentucky study showed lower dose submitted in Rx-to-OTC switch NDA led to 5% loss from baseline weight, carried similar adverse effect profile to Rx dose.

You may also be interested in...

Xenical OTC Actual Use Trial Shows Dose Compliance, Glaxo Says

Abuse was “extremely low” Glaxo researchers report at Vancouver meeting of the Obesity Society. Three-month, pharmacy-based trial offered 60 mg orlistat over-the-counter to consumers 18 and older.

Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date

FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts